000290073 001__ 290073
000290073 005__ 20260220120906.0
000290073 0247_ $$2doi$$a10.1016/j.jhepr.2024.101063
000290073 0247_ $$2altmetric$$aaltmetric:160674049
000290073 037__ $$aDKFZ-2024-00972
000290073 041__ $$aEnglish
000290073 082__ $$a610
000290073 1001_ $$0P:(DE-HGF)0$$aHoegen-Saßmannshausen, Philipp$$b0$$eFirst author
000290073 245__ $$aCarbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial
000290073 260__ $$aAmsterdam$$bElsevier$$c2024
000290073 3367_ $$2DRIVER$$aarticle
000290073 3367_ $$2DataCite$$aOutput Types/Journal article
000290073 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1715338837_25996
000290073 3367_ $$2BibTeX$$aARTICLE
000290073 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290073 3367_ $$00$$2EndNote$$aJournal Article
000290073 500__ $$a#EA:E050#
000290073 520__ $$aBackground & Aims:Inoperable hepatocellular carcinoma (HCC) can be treated by stereotactic body radiotherapy. However, carbon ion radiotherapy (CIRT) is more effective for sparing non-tumorous liver. High linear energy transfer could promote therapy efficacy. Japanese and Chinese studies on hypofractionated CIRT have yielded excellent results. Because of different radiobiological models and the different etiological spectrum of HCC, applicability of these results to European cohorts and centers remains questionable. The aim of this prospective study was to assess safety and efficacy and to determine the optimal dose of CIRT with active raster scanning based on the local effect model (LEM) I.Methods:CIRT was performed every other day in four fractions with relative biological effectiveness (RBE)-weighted fraction doses of 8.1–10.5 Gy (total doses 32.4–42.0 Gy [RBE]). Dose escalation was performed in five dose levels with at least three patients each. The primary endpoint was acute toxicity after 4 weeks.Results:Twenty patients received CIRT (median age 74.7 years, n = 16 with liver cirrhosis, Child-Pugh scores [CP] A5 [n = 10], A6 [n = 4], B8 [n = 1], and B9 [n = 1]). Median follow up was 23 months. No dose-limiting toxicities and no toxicities exceeding grade II occurred, except one grade III gamma-glutamyltransferase elevation 12 months after CIRT, synchronous to out-of-field hepatic progression. During 12 months after CIRT, no CP elevation occurred. The highest dose level could be applied safely. No local recurrence developed during follow up. The objective response rate was 80%. Median overall survival was 30.8 months (1/2/3 years: 75%/64%/22%). Median progression-free survival was 20.9 months (1/2/3 years: 59%/43%/43%). Intrahepatic progression outside of the CIRT target volume was the most frequent pattern of progression.Conclusions:CIRT of HCC yields excellent local control without dose-limiting toxicity.
000290073 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000290073 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000290073 7001_ $$aNaumann, Patrick$$b1
000290073 7001_ $$aHoffmeister-Wittmann, Paula$$b2
000290073 7001_ $$aBen Harrabi, Semi$$b3
000290073 7001_ $$aSeidensaal, Katharina$$b4
000290073 7001_ $$0P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aWeykamp, Fabian$$b5$$udkfz
000290073 7001_ $$aMielke, Thomas$$b6
000290073 7001_ $$aEllerbrock, Malte$$b7
000290073 7001_ $$00009-0007-7316-6422$$aHabermehl, Daniel$$b8
000290073 7001_ $$00000-0003-3843-101X$$aSpringfeld, Christoph$$b9
000290073 7001_ $$0P:(DE-He78)54a6641a6c26ddc49cc754740e90b438$$aDill, Michael$$b10$$udkfz
000290073 7001_ $$00000-0001-8888-1030$$aLongerich, Thomas$$b11
000290073 7001_ $$aSchirmacher, Peter$$b12
000290073 7001_ $$aMehrabi, Arianeb$$b13
000290073 7001_ $$aChang, De-Hua$$b14
000290073 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b15$$udkfz
000290073 7001_ $$0P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aJäkel, Oliver$$b16$$udkfz
000290073 7001_ $$aHaberer, Thomas$$b17
000290073 7001_ $$0P:(DE-HGF)0$$aCombs, Stephanie E.$$b18
000290073 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b19$$udkfz
000290073 7001_ $$aHerfarth, Klaus$$b20
000290073 7001_ $$aLiermann, Jakob$$b21
000290073 773__ $$0PERI:(DE-600)2972660-8$$a10.1016/j.jhepr.2024.101063$$gVol. 6, no. 6, p. 101063 -$$n6$$p101063$$tJHEP reports$$v6$$x2589-5559$$y2024
000290073 8564_ $$uhttps://inrepo02.dkfz.de/record/290073/files/1-s2.0-S2589555924000648-main.pdf$$yOpenAccess
000290073 8564_ $$uhttps://inrepo02.dkfz.de/record/290073/files/1-s2.0-S2589555924000648-main.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000290073 909CO $$ooai:inrepo02.dkfz.de:290073$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000290073 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000290073 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000290073 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)54a6641a6c26ddc49cc754740e90b438$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000290073 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000290073 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000290073 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000290073 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000290073 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000290073 9141_ $$y2024
000290073 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJHEP REP : 2022$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-07-05T06:57:05Z
000290073 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-07-05T06:57:05Z
000290073 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000290073 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-07-05T06:57:05Z
000290073 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJHEP REP : 2022$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000290073 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000290073 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000290073 9201_ $$0I:(DE-He78)D500-20160331$$kD500$$lNWG Experimentelle Hepatologie, Entzündung und Krebs$$x1
000290073 9201_ $$0I:(DE-He78)F240-20160331$$kF240$$lNWG Experimentelle Hepatologie, Entzündung und Krebs$$x2
000290073 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lE040 Med. Physik in der Strahlentherapie$$x3
000290073 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x4
000290073 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x5
000290073 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000290073 980__ $$ajournal
000290073 980__ $$aVDB
000290073 980__ $$aUNRESTRICTED
000290073 980__ $$aI:(DE-He78)E050-20160331
000290073 980__ $$aI:(DE-He78)D500-20160331
000290073 980__ $$aI:(DE-He78)F240-20160331
000290073 980__ $$aI:(DE-He78)E040-20160331
000290073 980__ $$aI:(DE-He78)HD01-20160331
000290073 980__ $$aI:(DE-He78)MU01-20160331
000290073 9801_ $$aFullTexts